The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes

Table 3 Multivariable model from SSc-ILD diagnosis to all-cause mortality

Variable	Hazard ratio	p	95% CI
GORD treatment status
No treatment	1.0
Single agent treatment (PPI)	0.5	0.031	0.3-0.9
Combination treatment (PPI + H2RA)	0.3	0.0009	0.2-0.6
PAH	4.3	< 0.0001	2.9-6.2
ILD treatment status
Mycophenolate^a	0.5	0.0093	0.3-0.9
Cyclophosphamide^b	1.3	0.15	0.9-2.0

GORD gastroesophageal reflux disease, PPI Proton Pump Inhibitor, H2RA Histamine 2 Receptor Antagonist, PAH Pulmonary Arterial Hypertension by international definition mean PAP > = 20 AND PCWP < = 15 AND PVR Woods unit > 3 Woods units on right heart catheter, ILD interstitial lung disease defined as the presence of characteristic pulmonary fibrosis on HRCT of the chest
^aNo treatment with mycophenolate used as reference
^bNo treatment with cyclophosphamide used as reference

ISSN: 1478-6362